

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
28 September 2023 (28.09.2023)



(10) International Publication Number
WO 2023/183377 A1

(51) International Patent Classification:

C07D 417/14 (2006.01) A61P 35/00 (2006.01)
A61K 31/506 (2006.01) A61P 37/00 (2006.01)
C07F 1/00 (2006.01)

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2023/015889

(22) International Filing Date:

22 March 2023 (22.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/322,955 23 March 2022 (23.03.2022) US

(71) Applicant: RIGEL PHARMACEUTICALS, INC.

[US/US]; 1180 Veterans Boulevard, South San Francisco,
California 94080 (US).

(72) Inventors: MAUNG, Jack; c/o Rigel Pharmaceuticals,

Inc., 1180 Veterans Boulevard, South San Francisco, Cal-
ifornia 94080 (US). CHEN, Yan; c/o Rigel Pharmaceu-
ticals, Inc., 1180 Veterans Boulevard, South San Francisco,
California 94080 (US). SHAW, Simon; c/o Rigel Pharma-
ceuticals, Inc., 1180 Veterans Boulevard, South San Fran-
cisco, California 94080 (US). SWEENEY, David; c/o Rigel
Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San
Francisco, California 94080 (US). MASUDA, Esteban; c/
o Rigel Pharmaceuticals, Inc., 1180 Veterans Boulevard,
South San Francisco, California 94080 (US).

(74) Agent: BURGESS, Steven, J. et al.; Klarquist, One World

Trade Center, Suite 1600, 121 SW Salmon Street, Portland,
Oregon 97204 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORS



Formula I

(57) Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula I (I) Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.



WO 2023/183377 A1